Shingles Vaccine Halves Serious Heart Events in Patients with Heart Disease, New Research Reveals

People living with pre-existing heart disease who received a shingles vaccine experienced nearly half the rate of serious heart-related events within a year compared with those who were not vaccinated, according to groundbreaking research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). These significant findings underscore a potentially broader protective role for the shingles vaccine, extending beyond its primary function of preventing herpes zoster.

The comprehensive study meticulously reviewed data from more than 246,822 adults across the United States, all of whom had been diagnosed with atherosclerotic heart disease – a condition characterized by the dangerous buildup of plaque in the arteries, which can lead to severe cardiovascular complications. The results add substantial weight to an accumulating body of evidence suggesting that the shingles vaccine may offer systemic benefits, including a reduced risk of serious conditions such as heart disease and even neurodegenerative disorders like dementia.

Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the lead author of the study, emphasized the growing recognition of the vaccine’s multifaceted advantages. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke, and death," Dr. Nguyen stated. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This observation highlights the potential for the vaccine to act as a crucial secondary prevention tool in vulnerable populations.

Understanding the Interplay: Shingles, Inflammation, and Cardiovascular Health

To fully appreciate the implications of this study, it is essential to understand the underlying mechanisms and the diseases involved. Herpes zoster, commonly known as shingles, is a painful viral infection caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After an initial chickenpox infection, VZV lies dormant in nerve cells and can reactivate years or even decades later, particularly in older adults or those with weakened immune systems. The hallmark symptom is a blistering rash, often accompanied by severe nerve pain (postherpetic neuralgia) that can persist for months or years. The Centers for Disease Control and Prevention (CDC) recommends the shingles vaccine for adults age 50 years and older, as well as younger individuals with compromised immune systems, due to the high incidence and debilitating nature of the disease. An estimated one in three Americans will develop shingles in their lifetime.

Atherosclerotic heart disease, on the other hand, is a progressive condition where plaque — a sticky substance made of fat, cholesterol, calcium, and other substances found in the blood — builds up inside the arteries. This buildup, known as atherosclerosis, hardens and narrows the arteries, restricting blood flow to vital organs. It is the underlying cause of conditions such as heart attack, stroke, peripheral artery disease, and heart failure, collectively representing the leading cause of death globally.

The emerging link between shingles and cardiovascular events stems from the systemic inflammatory response triggered by a shingles infection. Earlier research has convincingly demonstrated that an acute shingles infection can induce widespread inflammation throughout the body, activate blood platelets, and promote the formation of blood clots. This inflammatory cascade can damage the endothelium, the inner lining of blood vessels, making them more susceptible to plaque rupture and clot formation. Such events significantly increase the risk of acute myocardial infarction (heart attack), ischemic stroke, and venous thromboembolism (VTE) in the weeks and months following a shingles episode. By preventing the initial shingles infection, the vaccine effectively preempts this dangerous inflammatory surge, thereby potentially reducing the likelihood of these acute cardiovascular catastrophes.

A Chronology of Scientific Discovery: From Prevention to Broader Protection

The journey to understanding the shingles vaccine’s broader benefits has been incremental, building upon decades of virological and immunological research.

• Early 2000s: Recognition of the increased risk of cardiovascular events following acute infections, including influenza and pneumonia, began to solidify in the medical community. This laid theoretical groundwork for exploring similar links with herpes zoster.
• 2006: The first shingles vaccine, Zostavax, a live-attenuated vaccine, received approval in the United States. While effective, its efficacy waned over time, and it was contraindicated in immunocompromised individuals.
• Mid-2010s: Studies began to emerge detailing the heightened risk of stroke and heart attack in the period immediately following a shingles diagnosis. This evidence solidified the direct link between VZV reactivation and cardiovascular complications. For instance, a meta-analysis published in 2017 in the Journal of the American College of Cardiology highlighted a transient but significant increase in the risk of stroke and myocardial infarction post-shingles.
• 2017: A second-generation, recombinant zoster vaccine, Shingrix, was approved. Shingrix demonstrated superior efficacy (over 90% in preventing shingles) and longer-lasting protection compared to Zostavax, quickly becoming the preferred vaccine. This higher efficacy makes it a more potent tool for studying broader health outcomes.
• 2025 (Prior Study Mentioned): A pivotal study, preceding the current research, found that shingles vaccination was associated with a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially lasting up to eight years. This provided the first strong indication that the vaccine’s protective effects extended beyond simply preventing shingles itself.
• ACC.26 (Current Study): Dr. Nguyen’s team takes this research a critical step further by focusing specifically on individuals already diagnosed with atherosclerotic heart disease. This population, already at high risk for cardiovascular events, stands to gain the most from additional protective measures. The finding of a nearly 50% reduction in serious heart events in this group represents a significant leap in understanding the vaccine’s potential.

Robust Methodology Reveals Significant Risk Reduction

To execute their study, researchers leveraged TriNetX, an extensive federated research network containing de-identified electronic medical records from millions of Americans across numerous healthcare organizations. This vast dataset allowed for a powerful retrospective cohort analysis.

The study population comprised adults aged 50 years or older with a confirmed diagnosis of atherosclerotic heart disease between 2018 and 2025. The researchers meticulously constructed two balanced cohorts: 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, and an equal number of unvaccinated individuals. Crucially, both groups were rigorously matched on a wide array of demographic characteristics (age, sex, race, ethnicity) and other significant health conditions (e.g., diabetes, hypertension, hyperlipidemia, chronic kidney disease, smoking status), as well as socioeconomic factors (problems related to housing, economic circumstances, social environment, employment status, education, and literacy). This meticulous matching process aimed to minimize confounding variables and ensure that any observed differences in outcomes could be more confidently attributed to vaccination status.

The primary focus of the research was on heart-related outcomes occurring between one month and one year after vaccination (or within the same designated timeframe for the unvaccinated control group). The results were stark and consistent across all measures:

• Major Adverse Cardiac Events (MACE): Vaccinated individuals were 46% less likely to experience a major adverse cardiac event, a composite endpoint often including heart attack, stroke, and cardiovascular death.
• All-Cause Mortality: Strikingly, vaccinated participants showed a 66% reduced likelihood of dying from any cause within the study period.
• Specific Cardiovascular Events:
  • The risk of heart attack dropped by 32%.
  • The risk of stroke decreased by 25%.
  • The risk of heart failure was also reduced by 25%.

Dr. Nguyen underscored the profound clinical significance of these reductions. "These reductions are substantial and comparable to the benefits seen from quitting smoking," he noted, providing a powerful analogy that resonates with both clinicians and the public. He further emphasized that these findings reinforce and strengthen current public health recommendations for all adults over the age of 50 to receive the shingles vaccine.

Official Responses and Public Health Implications

The presentation of these findings at the American College of Cardiology’s Annual Scientific Session is in itself an endorsement of the study’s importance. The ACC, as a leading professional medical society for cardiovascular specialists, plays a crucial role in disseminating cutting-edge research that shapes clinical practice. While no direct statement from the ACC leadership was provided in the original text, the inclusion of this research at such a prominent scientific forum signals its potential to influence guidelines and patient care.

The CDC’s long-standing recommendation for shingles vaccination is primarily based on preventing the painful rash and its complications. However, this new data suggests an added layer of protection that could significantly impact cardiovascular health. Public health officials and healthcare providers can now leverage this evidence to bolster vaccine promotion efforts, especially among older adults and those with existing cardiovascular disease, who often face complex medication regimens and multiple health risks.

Dr. Nguyen articulated the broader societal value of these findings, particularly in the current environment. "Vaccines are one of the most important medicines we have to prevent disease," he stated. "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." This highlights the critical role of robust, peer-reviewed data in countering misinformation and empowering individuals to make informed health decisions.

Limitations, Future Directions, and Broader Impact

While the study offers compelling evidence, it is important to acknowledge its limitations and consider avenues for future research. The analysis specifically tracked outcomes during the first year after vaccination. While a previous study suggested benefits lasting up to eight years, the long-term effects beyond one year in this high-risk population still warrant further investigation.

A common challenge in observational studies like this is the potential for "healthy user bias." Individuals who choose to get vaccinated may also be more health-conscious overall, engaging in healthier behaviors (e.g., better diet, regular exercise, adherence to other medical advice) that independently contribute to better cardiovascular outcomes. While the researchers made considerable efforts to statistically adjust for numerous health and socioeconomic factors, it is inherently difficult to fully account for all such unmeasured confounders. However, the study’s exceptionally large sample size and sophisticated statistical approach provide strong evidence that the association between shingles vaccination and a meaningful reduction in heart risk is robust and clinically significant.

The broader implications of this research are substantial. It reinforces the growing understanding that infectious diseases are not isolated events but can have far-reaching systemic consequences, particularly for the cardiovascular system. Integrating vaccination strategies into comprehensive preventive cardiology approaches could become a standard practice, potentially leading to a measurable reduction in the global burden of heart disease. From an economic perspective, preventing heart attacks, strokes, and heart failure can lead to significant savings in healthcare costs, beyond the direct benefits of preventing shingles itself.

This study serves as a powerful reminder of the multifaceted benefits of vaccination and the dynamic nature of medical science. As Dr. Nguyen prepares to present his team’s findings, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," at Posters, Hall E, on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC, the medical community will undoubtedly be considering how these insights can be translated into improved patient outcomes and more effective public health strategies. The shingles vaccine, once seen primarily as a preventative measure for a painful rash, is now emerging as a potential guardian of the heart.